BFM
OTLK icon

Boothbay Fund Management’s Outlook Therapeutics OTLK Stock Holding History

Boothbay Fund Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-159,350
Closed -$851K – 1805
2024
Q3 		$851K Sell
159,350
-90,650
-36% -$663K 0.02% 803
2024
Q2 		$1.84M Buy
+250,000
New +$2.01M 0.04% 529

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's OTLK Position: Q4 2024 in Review

Boothbay Fund Management sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 159,350 shares — an estimated $851K sold.

Boothbay Fund Management first reported a position in OTLK in Q2 2024 and held it in 2 quarters. The position peaked at $1.84M in Q2 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Boothbay Fund Management reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 159,350 Outlook Therapeutics shares in Q4 2024, an estimated $851K.
  • Boothbay Fund Management first reported a position in Outlook Therapeutics in Q2 2024 and held it in 2 quarters.
  • Boothbay Fund Management's Outlook Therapeutics position peaked at $1.84M in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Boothbay Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.